PALO ALTO, Calif.--(BUSINESS WIRE)--Tidepool, a software company committed to innovations in diabetes management, is thrilled to announce a new data integration with continuous glucose monitoring (CGM ...

Abbott ($ABT) now has a mobile app to collect and share data for its continuous glucose monitor that doesn't require routine finger-stick calibration, FreeStyle Libre ...

- Findings from the RELIEF study in France showed for the first time, in the largest retrospective analysis of its kind of nearly 75,000 people living with diabetes, use of the FreeStyle Libre system ...

Abbott LaboratoriesABT announced positive results from the IMPACT trial on FreeStyle Libre. Data were presented at the American Diabetes Association's 76th Scientific Sessions. The randomized, ...

Abbott announced late-breaking clinical data that demonstrate the FreeStyle Libre 3 system has an overall mean absolute relative difference (MARD) of 7.9%, making it the first and only 14-day ...

Real-world data showed the use of a continuous glucose monitoring system was able to substantially reduce A1c levels among people with Type 2 diabetes regardless of whether they were taking insulin.

Data analyses show that people with Type 2 diabetes using GLP-1 medicines saw a significant improvement in their HbA1C after adding FreeStyle Libre technology to their regimen Better HbA1c results ...

Tidepool collaborates with Abbott for seamless data integration with its FreeStyle Libre portfolio in the U.S., expanding patient choice and streamlining diabetes care workflows. PALO ALTO, ...

MARD is considered the simplest measurement of sensor accuracy 2 and represents the difference between a CGM system's glucose readings and a reference blood glucose measurement. The lower the MARD, ...